Unisun® for Intratympanic Delivery
The Unisun® platform can be used with many drugs used to treat a variety of otic disorders, including Meniere’s disease, sudden sensorineural hearing loss, tinnitus, and autoimmune inner ear disease. Drugs include small molecules, peptides, monoclonal antibodies, proteins, and macromolecules.
Current drug delivery systems for the treatment of inner ear diseases offer either tight control of pharmacokinetic drug levels in the inner ear or a low cost of treatment, but not both. Because the Unisun® platform combines the use of uniform drug-loaded microspheres (for precise control of drug release) along with a fast film-forming agent (allowing for low cost, intratympanic delivery of the drug) it is well positioned for widespread clinical adoption.
Unisun® leverages enhanced Stratμm® microparticles for treating the inner ear
- Combines Stratμm® microspheres with a film-forming agent, or a film-forming agent on its own
- Film-forming agent uses a non-irritating aqueous base
- Film-forming agent dries quickly on warm biological surfaces
- Can be used to inject and set up highly concentrated depots of a drug
- Good for small molecules, proteins, peptides, and vaccines
Speak With An Expert
Nathan Dormer
Director, Drug Product Development
Nathan Dormer, Ph.D., is the Director of Drug Product Development at Adare Pharma Solutions and is responsible for pharmaceutical development activities at Adare’s Lenexa, KS and Philadelphia, PA facilities, where he supports a team of formulation scientists and analysts. He is a pharmaceutical scientist and bioengineer by training, with more than 16 years of experience developing microsphere-based solid oral and parenteral/implantable dosage forms in academic, innovator, and CDMO settings. Dr. Dormer earned his B.S. in Chemical Engineering and his Ph.D. (w/Honors) in Bioengineering from The University of Kansas while receiving NIH-sponsored Pharmaceutical Biotech Training.
